ES2134815T3 - Nuevos potentes inductores de la diferenciacion terminal y metodos de uso de los mismos. - Google Patents
Nuevos potentes inductores de la diferenciacion terminal y metodos de uso de los mismos.Info
- Publication number
- ES2134815T3 ES2134815T3 ES92922033T ES92922033T ES2134815T3 ES 2134815 T3 ES2134815 T3 ES 2134815T3 ES 92922033 T ES92922033 T ES 92922033T ES 92922033 T ES92922033 T ES 92922033T ES 2134815 T3 ES2134815 T3 ES 2134815T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- provides
- present
- different
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000011712 cell development Effects 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000005170 neoplastic cell Anatomy 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- -1 pyridineamino Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
- C07C233/92—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with at least one carbon atom of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Networks Using Active Elements (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA EL COMPUESTO QUE TIENE ESTRUCTURA (I), EN LA QUE CADA UNO DE R1 Y R2 SON INDEPENDIENTEMENTE ENTRE SI IGUALES O DIFERENTES DE, UNOS DE OTROS; CUANDO R1 Y R2 SON LOS MISMOS, CADA UNO ES UN ARILOAMINO SUSTITUIDO O NO SUSTITUIDO, CICLOALQUILAMINO, PIRIDINOAMINO, PIPERIDINO, (9 -PURINA DIFERENTES, R1 = R3 PENDIENTEMENTE LOS MISMOS O DIFERENTES UNOS DE OTROS, Y SON UN ATOMO DE HIDROGENO, UN GRUPO HIDROXILO, UN ALQUILO SUSTITUIDO O NO SUSTITUIDO, RAMIFICADO O NO RAMIFICADO, ALQUENILO, CICLOALQUILO, ARILO, ALQUILOXI, ARILOXI, ARILALILOXI, O GRUPO PIRIDINA, O R3 Y R4 UNIDOS JUNTAMENTE FORMAN UN GRUPO PIPERIDINA Y R2 ES UN HIDROXILAMINO, HIDROXILO, AMINO, ALQUILAMINO, DIALQUILAMINO O GRUPO ALQUILOXI; Y N ES UN NUMERO ENTERO DE 4 A 8. LA PRESENTE INVENCION TAMBIEN PROPORCIONA UN METODO DE INDUCIR SELECTIVAMENTE DIFERENCIACION TERMINAL DE CELULAS NEOPLASTICAS Y CON ELLO INHIBIR LA PROLIFERACION DE TALES CELULAS. INCLUSO LA PRESENTE INVENCION PROPORCIONA UN METODO DE TRATAMIENTO DE UN PACIENTE QUE TENGA UN TUMOR CARACTERIZADO POR LA PROLIFERACION DE CELULAS NEOPLASTICAS. POR ULTIMO, LA PRESENTE INVENCION PROPORCIONA UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN PORTADOR FARMACEUTICAMENTE ACEPTABLE Y UNA CANTIDAD TERAPEUTICAMENTE ACEPTABLE DEL COMPUESTO ANTERIOR.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/771,760 US5369108A (en) | 1991-10-04 | 1991-10-04 | Potent inducers of terminal differentiation and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2134815T3 true ES2134815T3 (es) | 1999-10-16 |
Family
ID=25092893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92922033T Expired - Lifetime ES2134815T3 (es) | 1991-10-04 | 1992-10-05 | Nuevos potentes inductores de la diferenciacion terminal y metodos de uso de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (3) | US5369108A (es) |
EP (1) | EP0642509B1 (es) |
JP (4) | JP3432823B2 (es) |
KR (2) | KR100263264B1 (es) |
AT (1) | ATE183185T1 (es) |
AU (1) | AU668696B2 (es) |
CA (1) | CA2120619C (es) |
CL (1) | CL2008002943A1 (es) |
DE (1) | DE69229800T2 (es) |
ES (1) | ES2134815T3 (es) |
FI (1) | FI941537A (es) |
HU (1) | HU225497B1 (es) |
RU (1) | RU2128643C1 (es) |
WO (1) | WO1993007148A1 (es) |
Families Citing this family (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5700811A (en) * | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5393902A (en) * | 1994-04-26 | 1995-02-28 | Lever Brothers Company, Division Of Conopco, Inc. | Process for the preparation of bis(amidocarboxylic acids) |
US5981597A (en) * | 1995-02-13 | 1999-11-09 | Trustees Of The University Of Pennsylvania | Differentiating agents for the treatment of inflammatory intestinal diseases |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
AUPO721997A0 (en) * | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
US7745142B2 (en) | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
EP1127054A4 (en) * | 1998-10-29 | 2006-11-02 | Bristol Myers Squibb Co | INHIBITORS OF IMPDH ENZYME |
EA007649B1 (ru) * | 1999-09-08 | 2006-12-29 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч | Ингибиторы гистондеацетилазы, вызывающие дифференцировку клеток, и их применение |
WO2001038322A1 (en) | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
AU2001290131B2 (en) * | 2000-09-29 | 2007-11-15 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
EP1598067B1 (en) * | 2000-09-29 | 2009-05-06 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage for the treatment of malaria |
GB0023983D0 (en) * | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
AR035659A1 (es) * | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
AR035513A1 (es) * | 2000-12-23 | 2004-06-02 | Hoffmann La Roche | Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos |
US7314953B2 (en) | 2001-03-27 | 2008-01-01 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US8026280B2 (en) | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
AR035455A1 (es) | 2001-04-23 | 2004-05-26 | Hoffmann La Roche | Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos |
US20040142859A1 (en) * | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
US20050227915A1 (en) * | 2001-05-02 | 2005-10-13 | Steffan Joan S | Methods and reagents for treating neurodegenerative diseases and motor deficit disorders |
US6784173B2 (en) * | 2001-06-15 | 2004-08-31 | Hoffmann-La Roche Inc. | Aromatic dicarboxylic acid derivatives |
AUPR738301A0 (en) * | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
US20040087657A1 (en) * | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
AU2003219803B8 (en) * | 2002-02-15 | 2005-08-25 | Sloan-Kettering Institute For Cancer Research | Method of treating TRX mediated diseases |
US20050288227A1 (en) * | 2002-02-15 | 2005-12-29 | Marks Paul A | Use of thioredoxin measurements for diagnostics and treatments |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
EP1487426B1 (en) * | 2002-03-04 | 2012-08-22 | Sloan-kettering Institute For Cancer Research | Methods of inducing terminal differentiation |
JP2005521401A (ja) | 2002-03-27 | 2005-07-21 | イミュネックス・コーポレーション | ポリペプチド産生を増加させる方法 |
CN100566711C (zh) * | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
EP1511477A4 (en) | 2002-05-22 | 2008-04-09 | Errant Gene Therapeutics Llc | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS |
GB0217777D0 (en) * | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
US6719310B1 (en) * | 2002-10-17 | 2004-04-13 | Teng Hsiang Lin | Self-movable vehicle |
US7098241B2 (en) | 2002-12-16 | 2006-08-29 | Hoffmann-La Roche Inc. | Thiophene hydroxamic acid derivatives |
WO2004059083A1 (ja) * | 2002-12-26 | 2004-07-15 | Canon Kabushiki Kaisha | カール低減剤、インクジェット用インク、インクジェット記録方法及びカール低減方法 |
US20040235733A1 (en) * | 2003-02-27 | 2004-11-25 | Steffan Joan S. | Methods and reagents for reducing polyglutamine toxicity |
JP2006523693A (ja) | 2003-04-01 | 2006-10-19 | メモリアル スローン−ケタリング キャンサー センター | ヒドロキサム酸化合物およびその使用方法 |
US7842835B2 (en) | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
DK1663194T3 (da) | 2003-08-26 | 2010-07-19 | Merck Hdac Res Llc | Anvendelse af SAHA til behandling af mesotheliom |
CN1964714B (zh) * | 2003-08-29 | 2011-09-28 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途 |
CA2542096A1 (en) * | 2003-10-09 | 2005-04-21 | Aton Pharma, Inc. | Thiophene and benzothiophene hydroxamic acid derivatives |
EP1694329A4 (en) * | 2003-11-26 | 2009-06-03 | Aton Pharma Inc | DIAMOND AND IMINODIACETIC ACID HYDROXAMINIC DERIVATIVES |
CA2552279C (en) | 2003-12-02 | 2014-07-15 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
US8017321B2 (en) * | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
ES2899590T3 (es) | 2004-01-23 | 2022-03-14 | Eden Research Plc | Métodos de eliminación de nematodos que comprenden la aplicación de un componente terpénico |
US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
US7345043B2 (en) * | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
JP4993374B2 (ja) * | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
EP2338332B1 (en) | 2004-05-20 | 2014-02-12 | Eden Research Plc | Hollow glucan particle or cell wall particle encapsulating a terpene component |
US20080090233A1 (en) * | 2004-05-27 | 2008-04-17 | The Regents Of The University Of Colorado | Methods for Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients |
EP1773761A1 (en) * | 2004-07-12 | 2007-04-18 | Merck & Co., Inc. | Histone deacetylase inhibitors |
CA2573509A1 (en) * | 2004-07-12 | 2006-02-16 | Merck & Co., Inc. | Histone deacetylase inhibitors |
CA2574035A1 (en) * | 2004-07-19 | 2006-02-23 | Sandro Belvedere | Histone deacetylase inhibitors |
CA2581639C (en) * | 2004-09-30 | 2016-07-26 | Molecular Devices Corporation | Luminescent lanthanide complexes |
US7772245B2 (en) | 2005-02-14 | 2010-08-10 | Miikana Therapeutics, Inc. | Inhibitors of histone deacetylase |
US7604939B2 (en) * | 2005-03-01 | 2009-10-20 | The Regents Of The University Of Michigan | Methods of identifying active BRM expression-promoting HDAC inhibitors |
US20100087328A1 (en) * | 2005-03-01 | 2010-04-08 | The Regents Of The University Of Michigan | Brm expression and related diagnostics |
MX2007011148A (es) * | 2005-03-11 | 2008-02-22 | Univ Colorado | Inhibidores de histona desacetilasa que sensibilizan celulas cancerosas respecto a los inhibidores de factor de crecimiento. |
CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
JP2008536924A (ja) | 2005-04-20 | 2008-09-11 | メルク エンド カムパニー インコーポレーテッド | ベンゾチオフェンヒドロキサミン酸のカーバメート、ウレア、アミドおよびスルホンアミド置換誘導体 |
CN101163690A (zh) * | 2005-04-20 | 2008-04-16 | 默克公司 | 苯并噻吩异羟肟酸衍生物 |
WO2006115845A1 (en) * | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Benzothiophene derivatives |
GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
TWI365068B (en) * | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
AU2006262166A1 (en) * | 2005-06-24 | 2007-01-04 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
WO2007017728A2 (en) * | 2005-08-05 | 2007-02-15 | Orchid Research Laboratories Limited | Novel heterocyclic compounds |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
WO2007055942A2 (en) * | 2005-11-03 | 2007-05-18 | Merck & Co., Inc. | Substituted nicotinamide compounds |
CA2626897A1 (en) | 2005-11-03 | 2007-05-18 | Joshua Close | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
CA2622136A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
JP2009514889A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにsaha及びボルテゾミブを用いる方法 |
WO2007054776A2 (en) * | 2005-11-10 | 2007-05-18 | Orchid Research Laboratories Limited | Stilbene like compounds as novel hdac inhibitors |
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
WO2007063267A1 (en) | 2005-11-30 | 2007-06-07 | Eden Research Plc | Terpene-containing compositions and methods of making and using them |
US20090012075A1 (en) * | 2006-01-12 | 2009-01-08 | Miller Thomas A | Fluorinated Arylamide Derivatives |
AU2007208495A1 (en) * | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Hydroxyalkylarylamide derivatives |
WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
AU2007221207A1 (en) * | 2006-02-28 | 2007-09-07 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007113644A2 (en) * | 2006-04-05 | 2007-10-11 | Orchid Research Laboratories Limited | New hdac inhibitors |
US20100137239A1 (en) * | 2006-04-24 | 2010-06-03 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
AU2007243519A1 (en) | 2006-04-26 | 2007-11-08 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
JP2009537529A (ja) * | 2006-05-18 | 2009-10-29 | メルク エンド カムパニー インコーポレーテッド | アリール縮合スピロ環化合物 |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
US7981874B2 (en) * | 2006-07-20 | 2011-07-19 | Merck Sharp & Dohme Corp. | Phosphorus derivatives as histone deacetylase inhibitors |
AU2007338601C1 (en) * | 2006-09-05 | 2014-07-24 | Emory University | Tyrosine kinase inhibitors for prevention or treatment of infection |
EP2068872A1 (en) * | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
WO2008033743A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety |
JP5563300B2 (ja) * | 2006-09-11 | 2014-07-30 | キュリス,インコーポレイテッド | 亜鉛結合部分を含むチロシンキナーゼインヒビター |
US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
SG174774A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
WO2008033745A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
KR20090077914A (ko) * | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | 항증식제로서의 다작용성 소분자 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
MX2009003405A (es) | 2006-09-28 | 2009-04-09 | Merck & Co Inc | Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa. |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
EA017198B1 (ru) * | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
EP2086323A4 (en) * | 2006-11-03 | 2010-01-06 | Univ Maryland | METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA |
WO2008097654A1 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Methods of using saha for treating hiv infection |
WO2008106524A1 (en) * | 2007-02-27 | 2008-09-04 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
CN101674833A (zh) * | 2007-03-20 | 2010-03-17 | 柯瑞斯公司 | 含有锌结合半族的Raf激酶抑制剂 |
US20100056522A1 (en) | 2007-03-28 | 2010-03-04 | Santen Pharmaceutical Co., Ltd. | Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient |
GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
AU2008271170A1 (en) * | 2007-06-27 | 2009-01-08 | Merck Sharp & Dohme Corp. | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
EP2190287B1 (en) * | 2007-09-10 | 2014-10-29 | Curis, Inc. | Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
US8119616B2 (en) * | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
US20090076154A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched vorinostat |
US8476255B2 (en) * | 2007-10-10 | 2013-07-02 | Orchid Chemicals & Pharmaceuticals Limited | Histone deacetylase inhibitors |
BRPI0817860A2 (pt) * | 2007-10-22 | 2019-09-24 | Orchid Res Laboratories Limited | inibidores de histona deacetilase |
US20110053991A1 (en) * | 2007-11-19 | 2011-03-03 | Gore Lia | Treatment of Histone Deacetylase Mediated Disorders |
CA2708281A1 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
NZ586955A (en) | 2008-02-07 | 2012-06-29 | Generics Uk Ltd | Novel process for the preparation of vorinostat |
EP2133334A1 (en) * | 2008-06-09 | 2009-12-16 | DAC S.r.l. | Heterocyclic derivatives as HDAC inhibitors |
RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
IT1392908B1 (it) | 2008-09-29 | 2012-04-02 | Italfarmaco Spa | Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative |
US20110212943A1 (en) * | 2008-10-15 | 2011-09-01 | Orchid Research Laboratories Limited | Novel bridged cyclic compounds as histone deacetylase inhibitors |
US8883851B2 (en) | 2008-10-15 | 2014-11-11 | Generics [Uk] Limited | Process for the preparation of vorinostat |
NZ593585A (en) | 2008-11-26 | 2012-12-21 | Generics Uk Ltd | Crystalline forms of vorinostat (suberoylanilide hydroxamic acid) |
RS54230B1 (en) | 2009-01-08 | 2015-12-31 | Curis Inc. | 3-KINASE PHOSPHOINOSITIDE INHIBITORS WITH ZINC BINDING PART |
CA2750413C (en) | 2009-01-23 | 2016-06-21 | Northlake Biosciences Llc | Hydroxamic acid derivatives |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
KR101168801B1 (ko) | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
US7994357B2 (en) * | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
EP2236503B1 (en) | 2009-04-03 | 2014-02-26 | NatureWise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
EP2454267A2 (en) | 2009-07-16 | 2012-05-23 | Royal College of Surgeons in Ireland | Metal complexes having dual histone deacetylase inhibitory and dna-binding activity |
EP2277387B1 (en) | 2009-07-22 | 2016-10-19 | NatureWise Biotech & Medicals Corporation | New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
WO2011056542A1 (en) | 2009-10-26 | 2011-05-12 | Ramot At Tel-Aviv University Ltd. | Cancer therapy with combinations of fts with hdac inhibitors |
US8217079B2 (en) | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
HUE026235T2 (en) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate |
CA2800143A1 (en) * | 2010-05-21 | 2011-11-24 | The Trustees Of Columbia University In The City Of New York | Selective hdac inhibitors |
WO2012019772A1 (en) * | 2010-08-12 | 2012-02-16 | Institut De Recherche Pour Le Developpement (I.R.D) | Method for treating protozoan parasitic diseases |
AT510456B1 (de) * | 2010-09-27 | 2012-11-15 | Univ Wien Tech | Thiazolamin-derivate als zelldifferenzierungsbeschleuniger |
DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
CN110063951A (zh) | 2011-03-09 | 2019-07-30 | 赛伦诺科学有限公司 | 利用组蛋白脱乙酰酶抑制物改善受损的内源纤维蛋白溶解作用的化合物和方法 |
ES2733128T3 (es) | 2011-04-01 | 2019-11-27 | Curis Inc | Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc |
PL2734510T4 (pl) | 2011-07-22 | 2019-05-31 | Massachusetts Inst Technology | Aktywatory deacetylaz histonowych klasy I (HDAC) i ich zastosowania |
US8921533B2 (en) | 2011-07-25 | 2014-12-30 | Chromatin Technologies | Glycosylated valproic acid analogs and uses thereof |
AU2012319188B2 (en) | 2011-10-03 | 2016-11-24 | Sloan-Kettering Institute For Cancer Research | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
WO2013151186A1 (ja) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | エリスロポエチン産生細胞の誘導方法 |
CN116574185A (zh) | 2012-07-25 | 2023-08-11 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
US9133105B2 (en) | 2013-03-06 | 2015-09-15 | C&C Biopharma, Llc | Transcription factor modulators |
US9878986B2 (en) | 2013-04-29 | 2018-01-30 | Chong Kun Dang Pharmaceutical Corp. | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
WO2015100363A1 (en) | 2013-12-23 | 2015-07-02 | The Trustees Of Columbia University In The City Of New York | Selective hdac6 inhibitors |
CN103922967B (zh) * | 2014-04-15 | 2016-06-01 | 北京化工大学 | 一种异羟肟酸类化合物及其在制备抑制癌细胞增殖和/或治疗癌症的药物中的应用 |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
WO2015184260A2 (en) | 2014-05-30 | 2015-12-03 | The Johns Hopkins University | Methods for treating mendelian disorders of the epigenetic machinery |
CN104292133B (zh) * | 2014-09-29 | 2016-06-01 | 烟台市华文欣欣医药科技有限公司 | 一种抗癌药物伏立诺他的合成方法 |
CN104292134B (zh) * | 2014-10-10 | 2016-06-22 | 广东药学院 | 异羟肟酸类化合物及其制备方法和应用 |
JP5993066B2 (ja) * | 2015-06-26 | 2016-09-14 | 大阪ガスケミカル株式会社 | アミド化合物、防カビ剤およびそれを用いる防カビ方法 |
ITUB20155193A1 (it) | 2015-11-03 | 2017-05-03 | Italfarmaco Spa | Sospensioni orali di Givinostat fisicamente e chimicamente stabili |
SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
AU2017233898B2 (en) | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
BR112018076812A2 (pt) * | 2016-06-21 | 2021-09-28 | The University Of Melbourne | Ativadores da latência de hiv |
WO2018015493A1 (en) | 2016-07-20 | 2018-01-25 | Royal College Of Surgeons In Ireland | Metal complexes having therapeutic applications |
CN106397102A (zh) * | 2016-08-29 | 2017-02-15 | 山东同成医药股份有限公司 | 卤代烃产品及其密封保温增压式生产方法 |
WO2018054960A1 (en) | 2016-09-21 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl |
AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
CN106905191B (zh) * | 2017-03-05 | 2019-03-29 | 北京化工大学 | 一种含有羟肟酸基团的氮芥类化合物及其制备方法和用途 |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2020014409A1 (en) | 2018-07-11 | 2020-01-16 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
AU2019340376A1 (en) | 2018-09-11 | 2021-04-08 | Curis Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN111533673B (zh) * | 2020-03-27 | 2022-05-20 | 徐州医科大学 | 一种含有缩氨基硫脲/缩氨基脲结构的化合物、其制备方法及医药用途 |
WO2023287984A1 (en) * | 2021-07-14 | 2023-01-19 | University Of Maryland, Baltimore | Suberoylanilide hydroxamic acid (saha) drugs, conjugates, and nanoparticles, and methods of use thereof |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
CN114621754A (zh) * | 2022-04-18 | 2022-06-14 | 武汉轻工大学 | 一种荧光探针的制备及其在组蛋白去乙酰化酶中的应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2895991A (en) * | 1959-07-21 | New chloromethylated amlides | ||
US2346665A (en) * | 1940-05-08 | 1944-04-18 | Du Pont | Acid |
US2279560A (en) * | 1940-05-08 | 1942-04-14 | Du Pont | Viscous hydrocarbon oil |
US2279973A (en) * | 1940-05-08 | 1942-04-14 | Du Pont | Stabilization of organic substances |
CH421933A (fr) * | 1964-02-03 | 1966-10-15 | Rhodiaceta | Procédé de fabrication d'amides mixtes d'acides carboxyliques |
US3450673A (en) * | 1965-09-07 | 1969-06-17 | Ashland Oil Inc | Polyurethane compositions from diaminimides |
FR1479260A (fr) * | 1965-12-06 | 1967-05-05 | Nouveaux dérivés acylés de la nu-hydroxyglycine | |
US3632783A (en) * | 1969-05-27 | 1972-01-04 | Hall Co C P | Treatment of mosquito bites employing certain tetraalkyl diamides |
US4056524A (en) * | 1974-04-09 | 1977-11-01 | Stauffer Chemical Company | Bis-substituted succinamides and their utility as herbicides |
US3875301A (en) * | 1974-04-30 | 1975-04-01 | Interx Research Corp | Useful tetraalkyl diamides in the treatment of poison ivy |
IT1123574B (it) * | 1979-09-10 | 1986-04-30 | Anic Spa | Processo per la produzione di diesterediammidi |
US4442305A (en) * | 1981-08-24 | 1984-04-10 | The United States Of America As Represented By The United States Department Of Energy | Polycatecholamide chelating agents |
US4480125A (en) * | 1981-11-16 | 1984-10-30 | Polaroid Corporation | Itaconamide compounds and method of preparation |
DE3305569A1 (de) * | 1983-02-18 | 1984-08-23 | Bayer Ag, 5090 Leverkusen | Biscarboxamide zur bekaempfung von erkrankungen sowie verfahren zu ihrer herstellung |
US4537781A (en) * | 1983-09-16 | 1985-08-27 | Research Corporation | Pharmaceutically useful malonamides |
NL8500249A (nl) * | 1984-02-17 | 1985-09-16 | Ppg Industries Inc | Bis(polybroomfenyl)diamiden en preparaten die ze bevatten. |
US4611053A (en) * | 1985-02-15 | 1986-09-09 | Sasa Michiyuki Mitch | Polyhydroxamide polymer |
JPS61205221A (ja) * | 1985-03-08 | 1986-09-11 | Univ Osaka | ニトリルとアミンからのアミドの製造方法 |
US4863967A (en) * | 1986-06-16 | 1989-09-05 | Research Corporation | N,N-diaminophthalamides |
US4882346A (en) * | 1987-06-16 | 1989-11-21 | The United States Of America As Reprsented By The Department Of Health And Human Services | Chemical differentiating agents |
US5330744A (en) * | 1988-11-14 | 1994-07-19 | Sloan-Kettering Institute For Cancer Research | Method for increasing sensitivity to chemically induced terminal differentiation |
US5175191A (en) * | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
AU5927190A (en) * | 1989-06-30 | 1991-01-17 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of terminal differentiation and methods of use thereof |
ES2128314T3 (es) * | 1989-11-14 | 1999-05-16 | Sloan Kettering Inst Cancer | Nuevos inductores potentes de diferenciacion terminal y metodo de utilizacion de los mismos. |
AU6659090A (en) * | 1989-11-16 | 1991-06-13 | Warner-Lambert Company | Acat inhibitors |
US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
HU211995B (en) * | 1992-06-30 | 1996-01-29 | Gyogyszerkutato Intezet | Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them |
-
1991
- 1991-10-04 US US07/771,760 patent/US5369108A/en not_active Ceased
-
1992
- 1992-10-05 EP EP92922033A patent/EP0642509B1/en not_active Expired - Lifetime
- 1992-10-05 ES ES92922033T patent/ES2134815T3/es not_active Expired - Lifetime
- 1992-10-05 CA CA002120619A patent/CA2120619C/en not_active Expired - Lifetime
- 1992-10-05 KR KR1019940701095A patent/KR100263264B1/ko not_active IP Right Cessation
- 1992-10-05 RU RU94021660A patent/RU2128643C1/ru active Protection Beyond IP Right Term
- 1992-10-05 AT AT92922033T patent/ATE183185T1/de active
- 1992-10-05 JP JP50710993A patent/JP3432823B2/ja not_active Expired - Lifetime
- 1992-10-05 DE DE69229800T patent/DE69229800T2/de not_active Expired - Lifetime
- 1992-10-05 WO PCT/US1992/008454 patent/WO1993007148A1/en active Application Filing
- 1992-10-05 AU AU28703/92A patent/AU668696B2/en not_active Expired
- 1992-10-05 HU HU9400959A patent/HU225497B1/hu unknown
-
1994
- 1994-03-31 FI FI941537A patent/FI941537A/fi not_active Application Discontinuation
- 1994-04-04 US US08/222,685 patent/US5932616A/en not_active Expired - Lifetime
-
1999
- 1999-05-18 US US09/314,195 patent/US6087367A/en not_active Expired - Fee Related
- 1999-10-30 KR KR1019997010081A patent/KR100258680B1/ko not_active IP Right Cessation
-
2002
- 2002-11-20 JP JP2002337049A patent/JP2003226680A/ja not_active Withdrawn
-
2007
- 2007-04-24 JP JP2007114876A patent/JP2007291110A/ja not_active Withdrawn
- 2007-09-19 JP JP2007242963A patent/JP2008069158A/ja not_active Withdrawn
-
2008
- 2008-10-02 CL CL2008002943A patent/CL2008002943A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US5932616A (en) | 1999-08-03 |
JP2007291110A (ja) | 2007-11-08 |
CL2008002943A1 (es) | 2009-03-06 |
DE69229800D1 (de) | 1999-09-16 |
KR100258680B1 (en) | 2000-05-15 |
EP0642509A4 (en) | 1995-01-31 |
JP2008069158A (ja) | 2008-03-27 |
AU2870392A (en) | 1993-05-03 |
ATE183185T1 (de) | 1999-08-15 |
JP3432823B2 (ja) | 2003-08-04 |
HUT67421A (en) | 1995-04-28 |
WO1993007148A1 (en) | 1993-04-15 |
RU2128643C1 (ru) | 1999-04-10 |
HU9400959D0 (en) | 1994-06-28 |
EP0642509B1 (en) | 1999-08-11 |
FI941537A (fi) | 1994-05-31 |
JPH07502494A (ja) | 1995-03-16 |
HU225497B1 (en) | 2007-01-29 |
JP2003226680A (ja) | 2003-08-12 |
CA2120619A1 (en) | 1993-04-15 |
DE69229800T2 (de) | 2000-04-27 |
US6087367A (en) | 2000-07-11 |
CA2120619C (en) | 2006-11-21 |
US5369108A (en) | 1994-11-29 |
KR100263264B1 (ko) | 2000-08-01 |
FI941537A0 (fi) | 1994-03-31 |
EP0642509A1 (en) | 1995-03-15 |
AU668696B2 (en) | 1996-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2134815T3 (es) | Nuevos potentes inductores de la diferenciacion terminal y metodos de uso de los mismos. | |
CA2190765A1 (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
RU94021660A (ru) | Новые соединения как потенциальные индукторы терминальной дифференциации клеток опухоли, фармацевтическая композиция на их основе и способ лечения | |
ES8401032A1 (es) | Procedimiento para la obtencion de 1,4-dihidropiridinas. | |
CZ85395A3 (en) | Derivatives of vaprooic and 1-valproenic acids and pharmaceutical preparations based thereon | |
FI954105A0 (fi) | Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä | |
CA2212326A1 (en) | O-carbamoyl-(d)-phenylalanilol compounds and process for preparing the same | |
ES8605506A1 (es) | Procedimiento para preparar derivados de piperidina | |
DK161185A (da) | Perhydrothiazepinderivater og fremgangsmaade til fremstilling deraf | |
NZ292782A (en) | Ant-inflammatory benzofuran and benzothiophene derivatives and medicaments thereof | |
ES8301927A1 (es) | Procedimiento de preparacion de acidos azabiciclohexano car-boxilicos y de sus sales | |
NO941166L (no) | Nye kraftige indusere for terminal differensiering og fremgangsmåter for anvendelse av disse | |
ES8103730A1 (es) | Procedimiento para la preparacion de una peptidamida | |
EP0617961A4 (en) | INHIBITOR OF EOSINOPHILIN INFILTRATION. | |
ES8204992A1 (es) | Procedimiento para la obtencion de compuestos poliazahetero-ciclicos | |
ES8506015A1 (es) | Procedimiento para la preparacion de esteres del acido alcoxivincaminico | |
HU9203000D0 (en) | Method for producing a preparative of medical effect | |
ES2009283A6 (es) | Procedimiento para preparar nuevos aminoacilatos de glicerol-acetal. | |
ES8400443A1 (es) | Mejoras introducidas en un procedimiento para la preparacion de hidroximidatos y tiolhidroximidatos heterobiciclicos y derivados ester carbamato de lso mismos. | |
IL68283A0 (en) | 4h-thiopyrans,their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 642509 Country of ref document: ES |